[Stereotactic body radiation therapy for patients with lung and liver oligometastases from colorectal cancer: a phase Ⅱ trial].
J Q Lei,W Y Liu,Y Tang,Y Tang,N Li,H Ren,Chi Yihebali,Y K Sun,W Zhang,X Y Bi,J J Zhao,H Fang,N N Lu,A P Zhou,S L Wang,Y W Song,Y P Liu,B Chen,S N Qi,J Q Cai,Y X Li,J Jin
DOI: https://doi.org/10.3760/cma.j.cn112152-20200413-00339
2022-01-01
Abstract: To explore the safety and effectiveness of stereotactic body radiation therapy (SBRT) for oligometastases from colorectal cancer (CRC). This is a prospective, single-arm phase Ⅱ trial. Patients who had histologically proven CRC, 1 to 5 detectable liver or lung metastatic lesions with maximum diameter of any metastases ≤5 cm were eligible. SBRT was delivered to all lesions. The primary endpoint was 3-year local control (LC). The secondary endpoints were treatment-related acute toxicities of grade 3 and above, 1-year and 3-year overall survival (OS) and progression free survival (PFS). Survival analysis was performed using the Kaplan-Meier method and Log rank test. Petients from 2016 to 2019 who were treated in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Forty-eight patients with 60 lesions were enrolled, including 37 liver lesions and 23 lung lesions. Forty-six patients had 1 or 2 lesions, with median diameter of 1.3 cm, the median biologically effective dose (BED(10)) was 100.0 Gy. The median follow-up was 19.5 months for all lesions. Twenty-five lesions developed local failure, the median local progression free survival was 15 months. The 1-year LC, OS and PFS was 70.2% (95% 63.7%~76.7%), 89.0% (95% 84.3%~93.7%) and 40.4% (95% 33.0%~47.8%). The univariate analysis revealed that planning target volume (PTV) and total dose were independent prognostic factors of LC (<0.05). For liver and lung lesions, the 1-year LC, OS and PFS was 58.7% and 89.4% (=0.015), 89.3% and 86.5% (=0.732), 30.5% and 65.6% (=0.024), respectively. No patients developed acute toxicity of grade 3 and above. SBRT is safe and effective treatment method for oligometastases from CRC under precise respiratory motion management and robust quality assurance.